Myriad Genetics

About: Myriad Genetics is a company organization based out in Munich, Germany. It is known for research contribution in the topics: Cancer & Breast cancer. The organization has 562 authors who have published 586 publications receiving 56046 citations. The organization is also known as: Myriad Genetics, Inc..

DNA-protein cross-linking applications for chromatin studies in vitro and in vivo.

Abstract: Publisher Summary Covalent protein–nucleic acid cross-linking is a powerful tool for the analysis of protein–DNA and protein–RNA interactions in various biological systems It allows a researcher to freeze protein–nucleic acid contacts within the context of a nucleoprotein complex and analyze cross-linked species by a variety of methods such as two-dimensional (2D) denaturing gel electrophoresis This chapter describes some of the methodical advances in the field of protein–nucleic acid covalent cross-linking applications The innovations discussed include (1) a fast, relatively noninvasive method of cross-linking by radical-producing chemicals, such as bleomycin–iron and phenanthroline–copper complexes, (2) applications of chemical and photochemical cross-linking techniques to nucleosome-containing complexes following in vitro nucleosome reconstitution on specific DNA, and (3) a time-resolved cross-linking technique for studies of postreplicative chromatin assembly based on the immunoenrichment of newly replicated DNA The chapter describes 5S rRNA gene nucleosome interactions with linker histones and transcription factor TFIIIA

Value of cell cycle progression (CCP) score to predict biochemical recurrence and definitive post-surgical pathology.

Abstract: 5043 Background: Prostate cancer (PCA) has a highly variable natural history and better tools are needed to more appropriately match treatment to a patient’s risk of progression. A prognostic mRNA ...

Compositions and therapeutic methods for viral infection

Abstract: Methods for inhibiting viral propagation and treating viral infection are provided which include administering to cells infected with viruses a compound capable of inhibiting viral budding from the infected host cells.

BRG1 is a tumor suppressor that is mutated in prostate and other cancer types

Abstract: The present invention relates to the relation of the BRG1 gene (also called SNF2α) to human cancers and its use in the diagnosis and prognosis of human cancer. The invention also relates to the therapy of human cancers which have a mutation in the BRG1 gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.